At a glance
ClinicalIndex Comparison RecordN/ACompleted· 54 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Rifaximin 550 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Diarrhea-Predominant Irritable Bowel Syndrome in Persian Gulf Veterans
In Brief
A clinical study evaluating Placebo and Rifaximin for Irritable Bowel Syndrome and Small Intestinal Bacterial Overgrowth. Completed, enrolled 54 participants across 1 site.
Detailed Summary
The purposes of this study are to estimate the burden of disease due to chronic gastrointestinal illness in PG veterans, to evaluate whether Small Bowel Bacterial Overgrowth (SBBO) is associated with chronic diarrhea in PG veterans, and to determine whether eradication of SBBO reduces symptoms of chronic diarrhea, abdominal pain and bloating in PG veterans.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedMay 2008
Primary CompletionOct 2008
Study CompletionDec 2013
TodayJul 2026
First PostedMay 20, 2008
Enrollment StartOct 1, 2007
Primary CompletionOct 1, 2008
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.1 years ago
Interventions
Placebodrug
orally two times per day for 14 days
Rifaximindrug
550 mg orally two times per day for 14 days